In year 2020, the Diabetes Canada guidelines recommended use of new classes, namely sodium-glucose co-transporter 2 (SGLT-2) inhibitors and glucagon-like peptide-1 receptor (GLP-1) agonist, as preferred second-line pharmaceutical agents for type 2 diabetes [3]. The gene discussed is SLC5A2; the disease is diabetes mellitus.